Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer.

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

These are drugs that target specific parts of cancer cells or nearby cells that help them grow. So far, these drugs have only been found to be useful for some non-small cell lung cancers ... the ...

Relevance section written by JCO Clinical Cancer Informatics Associate Editor Ziad Bakouny, MD, MSc. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model was ...

Different types of cancer have distinct molecular “fingerprints” that can be identified in the early stages of the disease with remarkable accuracy. Small, portable scanners can detect these ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...

Russia has reportedly developed a vaccine against cancer that it will launch early next year. The jab, which will be free of ...

For noncirrhotic patients with liver cancer, surgery is the treatment of choice. Surgical resection, in which your surgeon removes the cancerous part of the liver, offers the best possibility for a ...

CAR T cell therapy harnesses ... YTHDF2 switches on genes that help cancer cells produce a stable energy source to fuel the cells' ability to grow and spread. Moreover, this protein helps cancer ...